Satoh Kasumi, Nakae Hajime
Advanced Emergency and Critical Care Center, Akita University Hospital, Akita, Japan.
Front Nutr. 2021 Oct 11;8:749570. doi: 10.3389/fnut.2021.749570. eCollection 2021.
, a traditional Japanese herbal medicine (Kampo), has been used to treat abdominal distention of the middle yang stage pattern. The use of has not been thoroughly investigated in critical care. To investigate a new Kampo approach to defecation control in critically ill patients, our study aimed to assess the effects of on fecal management. We analyzed 30 consecutive patients treated with in the intensive care unit (ICU) between March 2017 and February 2021. The eligibility criteria were patients who were newly prescribed in the ICU during the study period. Exclusion criteria were patients who were started on other laxatives within one day of beginning . The study's primary outcome was defecation volume three days before and three days after starting . We recorded the most dominant stool quality within three days after the start of . Twenty-one patients were included in the analysis. The median age was 69.0 years, and the median sequential organ failure assessment score on admission to the ICU was 6.0. Major diseases included trauma, pancreatitis, and burns. Administration of resulted in defecation in 17 of twenty-one patients (81.0%). Comparison of defecation volume between 3 days before administration and three days, including the day of administration, showed that defecation volume increased significantly after administration, with a median of 0 to 360 g ( < ). At the three-day follow-up, six of 17 (35.3%) patients defecated on the day of administration, and nine (52.9%) defecated on the day after administration. One patient was judged to have excessive defecation, and administration was discontinued. Stool quality was normal in one (5.9%) of the 17 patients, soft-formed in two (11.8%), loose-unformed in 11 (64.7%), and liquid in three (17.6%). administration in critically ill patients caused defecation in 81% of the patients and significantly increased stool volume. The novelty of this study is that it sheds light on the Kampo treatment of defecation control in critically ill patients. In addition to the present report, further studies are warranted to quantify the therapeutic efficacy and safety of .
[方剂名称]是一种传统的日本草药（汉方），已被用于治疗中阳证型的腹胀。在重症监护中，[方剂名称]的使用尚未得到充分研究。为了研究一种新的汉方方法来控制重症患者的排便，我们的研究旨在评估[方剂名称]对粪便管理的影响。我们分析了2017年3月至2021年2月期间在重症监护病房（ICU）连续接受[方剂名称]治疗的30例患者。纳入标准为在研究期间在ICU新开具[方剂名称]的患者。排除标准为在开始使用[方剂名称]后一天内开始使用其他泻药的患者。该研究的主要结局是开始使用[方剂名称]前三天和开始使用后三天的排便量。我们记录了开始使用[方剂名称]后三天内最主要的粪便质量。21例患者纳入分析。中位年龄为69.0岁，入住ICU时的中位序贯器官衰竭评估评分是6.0。主要疾病包括创伤、胰腺炎和烧伤。使用[方剂名称]后，21例患者中有17例（81.0%）排便。比较使用[方剂名称]前三天和包括使用[方剂名称]当天在内的三天的排便量，结果显示使用[方剂名称]后排便量显著增加，中位数从0增加到360克（P<[具体值]）。在三天随访时，17例患者中有6例（35.3%）在使用[方剂名称]当天排便，9例（52.9%）在使用后一天排便。1例患者被判定排便过多，停用了[方剂名称]。17例患者中1例（5.9%）粪便质量正常，2例（11.8%）为软便，11例（64.7%）为稀软便，3例（17.6%）为水样便。[方剂名称]用于重症患者可使81%的患者排便，并显著增加粪便量。本研究的新颖之处在于揭示了汉方对重症患者排便控制的治疗作用。除本报告外，有必要进一步研究以量化[方剂名称]的治疗效果和安全性。
